NextCure Gelecekteki Büyüme

Future kriter kontrolleri 0/6

NextCure's earnings are forecast to decline at 6.1% per annum while its annual revenue is expected to grow at 75.8% per year. EPS is expected to grow by 30% per annum.

Anahtar bilgiler

-6.1%

Kazanç büyüme oranı

30.0%

EPS büyüme oranı

Biotechs kazanç büyümesi27.1%
Gelir büyüme oranı75.8%
Gelecekteki özkaynak getirisin/a
Analist kapsamı

Low

Son güncelleme25 Sep 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

We're Keeping An Eye On NextCure's (NASDAQ:NXTC) Cash Burn Rate

Jul 17
We're Keeping An Eye On NextCure's (NASDAQ:NXTC) Cash Burn Rate

We're Keeping An Eye On NextCure's (NASDAQ:NXTC) Cash Burn Rate

Mar 23
We're Keeping An Eye On NextCure's (NASDAQ:NXTC) Cash Burn Rate

We're Keeping An Eye On NextCure's (NASDAQ:NXTC) Cash Burn Rate

Dec 09
We're Keeping An Eye On NextCure's (NASDAQ:NXTC) Cash Burn Rate

Will NextCure (NASDAQ:NXTC) Spend Its Cash Wisely?

Aug 23
Will NextCure (NASDAQ:NXTC) Spend Its Cash Wisely?

Is NextCure (NASDAQ:NXTC) In A Good Position To Deliver On Growth Plans?

May 10
Is NextCure (NASDAQ:NXTC) In A Good Position To Deliver On Growth Plans?

We're Keeping An Eye On NextCure's (NASDAQ:NXTC) Cash Burn Rate

Nov 22
We're Keeping An Eye On NextCure's (NASDAQ:NXTC) Cash Burn Rate

Estimating The Intrinsic Value Of NextCure, Inc. (NASDAQ:NXTC)

Aug 09
Estimating The Intrinsic Value Of NextCure, Inc. (NASDAQ:NXTC)

NextCure GAAP EPS of -$0.59

Aug 04

We're Not Very Worried About NextCure's (NASDAQ:NXTC) Cash Burn Rate

May 02
We're Not Very Worried About NextCure's (NASDAQ:NXTC) Cash Burn Rate

NextCure: Large Upside With Downside Protected By Cash Pile

Sep 29

NextCure (NXTC) Presents at 7th Annual Truist Securities Life Sciences Summit - Slideshow

May 10

NextCure EPS misses by $0.01

May 06

Here's What NextCure, Inc.'s (NASDAQ:NXTC) Shareholder Ownership Structure Looks Like

Feb 12
Here's What NextCure, Inc.'s (NASDAQ:NXTC) Shareholder Ownership Structure Looks Like

NextCure's (NASDAQ:NXTC) Shareholders Are Down 80% On Their Shares

Jan 08
NextCure's (NASDAQ:NXTC) Shareholders Are Down 80% On Their Shares

NextCure provides update on NC318 clinical program

Dec 17

Kazanç ve Gelir Büyüme Tahminleri

NasdaqGS:NXTC - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
TarihGelirKazançlarSerbest Nakit AkışıFaaliyetlerden NakitAvg. Analist Sayısı
12/31/2026N/A-70N/AN/A1
12/31/2025N/A-49N/AN/A3
12/31/2024N/A-53N/AN/A3
6/30/2024N/A-61-46-46N/A
3/31/2024N/A-64-51-51N/A
12/31/2023N/A-63-54-53N/A
9/30/2023N/A-66-53-51N/A
6/30/2023N/A-70-55-53N/A
3/31/2023N/A-70-55-53N/A
12/31/2022N/A-75-56-54N/A
9/30/2022N/A-74-61-58N/A
6/30/2022N/A-73-58-56N/A
3/31/2022N/A-73-61-59N/A
12/31/2021N/A-69-60-57N/A
9/30/2021N/A-68-53-50N/A
6/30/2021N/A-66-57-53N/A
3/31/2021N/A-63-55-48N/A
12/31/202022-37-52-45N/A
9/30/202024-32-56-49N/A
6/30/202026-24-47-41N/A
3/31/202027-18-43-39N/A
12/31/20196-34-39-36N/A
9/30/20194-30-8-3N/A
6/30/20193-27-40N/A
3/31/20191-2426N/A
12/31/2018N/A-2358N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: NXTC is forecast to remain unprofitable over the next 3 years.

Kazançlar ve Piyasa: NXTC is forecast to remain unprofitable over the next 3 years.

Yüksek Büyüme Kazançları: NXTC is forecast to remain unprofitable over the next 3 years.

Gelir ve Pazar: NXTC is forecast to have no revenue next year.

Yüksek Büyüme Geliri: NXTC is forecast to have no revenue next year.


Hisse Başına Kazanç Büyüme Tahminleri


Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: Insufficient data to determine if NXTC's Return on Equity is forecast to be high in 3 years time


Büyüyen şirketleri keşfedin